gMG results from harmful anti-AChR or anti-MuSK antibodies produced by your immune system that get in the way of signals in the neuromuscular junction.

This disruption can lead to muscle weakness, muscle fatigue, and other symptoms that people living with gMG experience.

These harmful antibodies stay in your body longer than normal because of the immune system protein FcRn, also called neonatal Fc receptor.

Our cells have a system that removes waste, which can include antibodies. FcRn is in charge of saving antibodies from being swept up by the waste clearance system.

This occurs by a process of elimination. Think of it as a dance competition.

Only the antibodies that find an FcRn partner can stay, while all the rest have to leave. FcRn essentially decides which antibodies get to stay and which need to leave.

In people living with gMG, the harmful antibodies take over and too many of them dance with FcRn.

By binding with FcRn, these harmful antibodies can remain in your system for an extended period of time and continue to damage the neuromuscular junction.

RYSTIGGO works by targeting and binding to FcRn.

During a treatment cycle, RYSTIGGO can jump onto the dance floor and compete against harmful antibodies. RYSTIGGO is a stronger dance partner and more likely to dance with FcRn, leaving fewer dance partners for the harmful antibodies, which get broken down in the cell normally.

This is how RYSTIGGO reduces the overall levels of harmful antibodies during a treatment cycle.

Which means there are fewer harmful antibodies that can interfere with signals between nerves and muscles.

Individual results may vary, and not all people will experience improvements.

The exact mechanism by which RYSTIGGO works in gMG is unknown.